Related Experiment Video
Updated: Jun 3, 2026
DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Construction of recombinant lentivirus vector for tumor vasoinhibitory peptide alphastatin gene delivery
1Department of Neurosurgery, First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Shaanxi 710061, P.R. China.
Abstract:
Angiogenesis is a prerequisite for tumor progression and metastasis. Alphastatin, as an endogenous angiogenesis inhibitor, was recently used as an anticancer agent in several tumor models. We constructed recombinant self-inactivating lentivirus vectors expressing alphastatin and evaluated their ability to transfer genes into human umbilical vein endothelial cells (HUVECs) as well as their antiangiogenic activities in vitro. Recombinant self-inactivating lentiviral vectors efficiently and stably transduced endothelial cells, and lentivirus-transduced HUVECs were capable of sustainedly secreting the antiangiogenesis peptide alphastatin. Long-term expression and secretion of alphastatin resulted in significant inhibition of endothelial cell angiogenesis induced by vascular endothelial growth factor. This report presents the first use of lentivirus-based vectors to deliver the endogenous angiogenesis inhibitor alphastatin, and suggests the potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of cancer.
Insights
This study demonstrates that lentiviral vectors can deliver the angiogenesis inhibitor alphastatin into endothelial cells, effectively inhibiting tumor growth. This approach shows promise for antiangiogenic gene therapy in cancer treatment.
Area of Science:
- Molecular Biology
- Oncology
- Biotechnology
Background:
- Angiogenesis is crucial for tumor growth and metastasis.
- Alphastatin is an endogenous inhibitor of angiogenesis with anticancer potential.
- Gene therapy offers a novel approach to cancer treatment.
Purpose of the Study:
- To develop lentivirus-based vectors for delivering alphastatin.
- To evaluate the gene transfer efficiency and antiangiogenic activity of these vectors in vitro.
- To assess the potential of alphastatin gene therapy for cancer treatment.
Main Methods:
- Construction of recombinant self-inactivating lentivirus vectors expressing alphastatin.
- Gene transfer into human umbilical vein endothelial cells (HUVECs).
- In vitro evaluation of antiangiogenic activity, including inhibition of vascular endothelial growth factor (VEGF)-induced angiogenesis.
Main Results:
- Lentiviral vectors efficiently and stably transduced HUVECs.
- Transduced HUVECs sustainedly secreted alphastatin.
- Long-term alphastatin secretion significantly inhibited endothelial cell angiogenesis.
Conclusions:
- Lentivirus-based delivery of alphastatin is effective in inhibiting angiogenesis.
- This study presents the first use of lentiviral vectors for alphastatin delivery.
- Alphastatin gene therapy using lentiviral vectors holds potential for cancer treatment.
